Physician profile
William T Chen
NPI 1467546051
$13,024.06
in general payments reported to CMS, 2019-2025
31 companies · $2,597 in 2025
The $2,597 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,656 · 2020: $795 · 2021: $4,466 · 2022: $797 · 2023: $1,023 · 2024: $1,690 · 2025: $2,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,309.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,746.88 | 2019-2025 | General - Hemostasis, General - Biliary Devices, Axios |
| Abbvie INC. | $1,983.95 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Braintree Laboratories, INC. | $660.69 | 2021-2025 | Suflave, Sutab |
| Janssen Biotech, INC. | $510.15 | 2020-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $499.44 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Olympus America INC. | $366.29 | 2019-2025 | Evis Exera III Colonovideoscope, Evis Exera III Xenon Light Source, Gastrointestinal Videoscope |
| Janssen Pharmaceuticals, INC | $328.89 | 2020-2021 | |
| Lucid Diagnostics INC. | $290.01 | 2024-2025 | |
| Ambu INC. | $284.88 | 2020-2021 | |
| Pfizer INC. | $283.94 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $257.84 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $230.59 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $225.68 | 2023-2024 | Voquezna |
| Laborie Medical Technologies Corp. | $177.93 | 2024 | Alphaone |
| Ardelyx, INC. | $154.28 | 2023-2025 | Ibsrela |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $138.02 | 2025 | |
| Celgene Corporation | $133.36 | 2022-2024 | Zeposia |
| Novo Nordisk INC | $124.99 | 2023 | |
| Lilly USA, LLC | $88.21 | 2024 | Omvoh |
| Fujifilm Healthcare Americas Corporation | $85.82 | 2024 | |
| Nestle Healthcare Nutrition INC. | $79.87 | 2022-2023 | |
| Madrigal Pharmaceuticals | $56.57 | 2024 | Resmetirom |
| Ironwood Pharmaceuticals, INC | $55.71 | 2021-2024 | |
| Genzyme Corporation | $55.29 | 2022 | |
| Medtronic, INC. | $47.77 | 2024-2025 | Barrx, Gi Genius |
| Qol Medical, LLC | $46.35 | 2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $29.36 | 2025 | |
| Ferring Pharmaceuticals INC. | $28.30 | 2019-2021 | |
| Cook Medical LLC | $24.76 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.03 | 2022 | |
| Merck Sharp & Dohme LLC | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.